Inherited thrombophilia and pregnancy complications revisited

Marc A. Rodger, Michael Paidas, McLintock Claire, Saskia Middeldorp, Susan Kahn, Ida Martinelli, William Hague, Karen Rosene Montella, Ian Greer

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss. An inherited thrombophilia is only one of many factors that lead to development of these diseases and is unlikely to be the unique factor that should drive management in subsequent pregnancies. The paucity of evidence for benefit, coupled with a small potential for harm, suggests that low molecular weight heparin should be considered an experimental drug for these indications until data from controlled trials are published. At present, women with a history of placenta-mediated pregnancy complications, with or without a thrombophilia, should be followed closely without routine prophylactic low molecular weight heparin other than for prevention of venous thromboembolism in limited circumstances.

Original languageEnglish
Pages (from-to)320-324
Number of pages5
JournalObstetrics and Gynecology
Volume112
Issue number2 PART 1
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Thrombophilia
Pregnancy Complications
Low Molecular Weight Heparin
Placenta
Pregnancy
Venous Thromboembolism
Fetal Development
Pre-Eclampsia
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Rodger, M. A., Paidas, M., Claire, M., Middeldorp, S., Kahn, S., Martinelli, I., ... Greer, I. (2008). Inherited thrombophilia and pregnancy complications revisited. Obstetrics and Gynecology, 112(2 PART 1), 320-324. https://doi.org/10.1097/AOG.0b013e31817e8acc

Inherited thrombophilia and pregnancy complications revisited. / Rodger, Marc A.; Paidas, Michael; Claire, McLintock; Middeldorp, Saskia; Kahn, Susan; Martinelli, Ida; Hague, William; Rosene Montella, Karen; Greer, Ian.

In: Obstetrics and Gynecology, Vol. 112, No. 2 PART 1, 08.2008, p. 320-324.

Research output: Contribution to journalArticle

Rodger, MA, Paidas, M, Claire, M, Middeldorp, S, Kahn, S, Martinelli, I, Hague, W, Rosene Montella, K & Greer, I 2008, 'Inherited thrombophilia and pregnancy complications revisited', Obstetrics and Gynecology, vol. 112, no. 2 PART 1, pp. 320-324. https://doi.org/10.1097/AOG.0b013e31817e8acc
Rodger, Marc A. ; Paidas, Michael ; Claire, McLintock ; Middeldorp, Saskia ; Kahn, Susan ; Martinelli, Ida ; Hague, William ; Rosene Montella, Karen ; Greer, Ian. / Inherited thrombophilia and pregnancy complications revisited. In: Obstetrics and Gynecology. 2008 ; Vol. 112, No. 2 PART 1. pp. 320-324.
@article{187d4085149a422b926af5b3e86b2667,
title = "Inherited thrombophilia and pregnancy complications revisited",
abstract = "Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss. An inherited thrombophilia is only one of many factors that lead to development of these diseases and is unlikely to be the unique factor that should drive management in subsequent pregnancies. The paucity of evidence for benefit, coupled with a small potential for harm, suggests that low molecular weight heparin should be considered an experimental drug for these indications until data from controlled trials are published. At present, women with a history of placenta-mediated pregnancy complications, with or without a thrombophilia, should be followed closely without routine prophylactic low molecular weight heparin other than for prevention of venous thromboembolism in limited circumstances.",
author = "Rodger, {Marc A.} and Michael Paidas and McLintock Claire and Saskia Middeldorp and Susan Kahn and Ida Martinelli and William Hague and {Rosene Montella}, Karen and Ian Greer",
year = "2008",
month = "8",
doi = "10.1097/AOG.0b013e31817e8acc",
language = "English",
volume = "112",
pages = "320--324",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2 PART 1",

}

TY - JOUR

T1 - Inherited thrombophilia and pregnancy complications revisited

AU - Rodger, Marc A.

AU - Paidas, Michael

AU - Claire, McLintock

AU - Middeldorp, Saskia

AU - Kahn, Susan

AU - Martinelli, Ida

AU - Hague, William

AU - Rosene Montella, Karen

AU - Greer, Ian

PY - 2008/8

Y1 - 2008/8

N2 - Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss. An inherited thrombophilia is only one of many factors that lead to development of these diseases and is unlikely to be the unique factor that should drive management in subsequent pregnancies. The paucity of evidence for benefit, coupled with a small potential for harm, suggests that low molecular weight heparin should be considered an experimental drug for these indications until data from controlled trials are published. At present, women with a history of placenta-mediated pregnancy complications, with or without a thrombophilia, should be followed closely without routine prophylactic low molecular weight heparin other than for prevention of venous thromboembolism in limited circumstances.

AB - Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss. An inherited thrombophilia is only one of many factors that lead to development of these diseases and is unlikely to be the unique factor that should drive management in subsequent pregnancies. The paucity of evidence for benefit, coupled with a small potential for harm, suggests that low molecular weight heparin should be considered an experimental drug for these indications until data from controlled trials are published. At present, women with a history of placenta-mediated pregnancy complications, with or without a thrombophilia, should be followed closely without routine prophylactic low molecular weight heparin other than for prevention of venous thromboembolism in limited circumstances.

UR - http://www.scopus.com/inward/record.url?scp=51649086196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649086196&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e31817e8acc

DO - 10.1097/AOG.0b013e31817e8acc

M3 - Article

C2 - 18669729

AN - SCOPUS:51649086196

VL - 112

SP - 320

EP - 324

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2 PART 1

ER -